SEC For	m 4																			
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COM Washington, D.C. 20549														OMB	APPRO	VAL	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).						suant	to Se	ction 16(a	l) of the S	ecurit	NEFICI ies Exchar mpany Act		Est			er: verage burde sponse:	3235-0287 n 0.5			
1. Name and Address of Reporting Person <sup>*</sup> Blum Robert I						2. Issuer Name and Ticker or Trading Symbol <u>CYTOKINETICS INC</u> [ CYTK ]									elationship c eck all applic X Directo	able)	Reporting Person(s) to Is ble) 10% (			
(Last) (First) (Middle) 350 OYSTER POINT BLVD						3. Date of Earliest Transaction (Month/Day/Year) 08/17/2022									X Officer (give title below) President			Other (specify below)		
(Street) SOUTH SAN FRANCISCO CA 94080					4.	Line									ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S		(Zip)	n Doriu		0.50		tion An	auirod	Die	noooda	f or D		Finially	. Ourpad					
Table I - Non-Deriva   1. Title of Security (Instr. 3) 2. Transa Date (Month/D					action	ction 2A. Deeme Execution			, 3. Transaction Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3,		A) or	5. Amour Securitie Beneficia Owned F	nt of 6. C s Fon ally (D) following (I) (I		n: Direct or Indirect	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) (D)	or I	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock (				08/17	7/2022				<b>M</b> <sup>(1)</sup>		10,00	0 A	· _	\$7.96	419	419,124		D		
Common Stock 08,				08/17	7/2022				S <sup>(1)</sup>		10,00	1 0		\$ <mark>50.1</mark> 1	1 409	409,124		D		
Common Stock															2,0	2,083			by Trust 1 <sup>(2)</sup>	
Common Stock															2,0	083			by Trust 2 <sup>(3)</sup>	
		-	Table II -	Deriva (e.g., p	tive uts,	Secu calls	uritie s, wa	es Acq arrants	uired, I , optio	Disp ns, c	osed of, converti	, or Be ble sec	nefic curit	cially ies)	Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		nount	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nu of	mber						
Non- Qualified Stock Option	\$7.96	08/17/2022			M <sup>(1)</sup>			10,000	03/26/20	15	02/26/2025	Commo Stock	<sup>n</sup> 10	),000	\$0	49,20	8	D		

Explanation of Responses:

(Right to Buy)

1. Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021.

2. Shares held by The Bridget Blum 2003 Irrevocable Trust.

3. Shares held by The Brittany Blum 2003 Irrevocable Trust.

/s/ John Faurescu, attorney-infact for Mr. Blum

08/19/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.